Back

Minor intron splicing efficiency increases with the development of lethal prostate cancer

Augspach, A.; Drake, K.; Roma, L.; Qian, E.; Lee, S. R.; Clarke, D.; Kumar, S.; Jaquet, M.; Gallon, J.; Bolis, M.; Triscott, J.; Galvan, J. A.; Chen, Y.; Thalmann, G.; Kruithof-de Julio, M.; Theurillat, J.-P. P.; Wuchty, S.; Gerstein, M.; Piscuoglio, S.; Kanadia, R.; Rubin, M. A.

2021-12-10 cancer biology
10.1101/2021.12.09.471104 bioRxiv
Show abstract

Here we explored the role of minor spliceosome (MiS) function and minor intron-containing gene (MIG) expression in prostate cancer (PCa). We show MIGs are enriched as direct interactors of cancer-causing genes and their expression discriminates PCa progression. Increased expression of MiS U6atac snRNA, including others, and 6x more efficient minor intron splicing was observed in castration-resistant PCa (CRPC) versus primary PCa. Notably, androgen receptor signalling influenced MiS activity. Inhibition of MiS through siU6atac in PCa caused minor intron mis-splicing and aberrant expression of MIG transcripts and encoded proteins, which enriched for MAPK activity, DNA repair and cell cycle. Single cell-RNAseq confirmed cell cycle defects and lineage dependency on the MiS from primary to CRPC and neuroendocrine PCa. siU6atac was [~]50% more efficient in lowering tumor burden of CRPC cells and organoids versus current state-of-the-art combination therapy. In all, MiS is a strong therapeutic target for lethal PCa and potentially other cancers. Graphical AbstractU6atac expression, MiS activity, and minor intron splicing correlate with PCa therapy resistance and PCa progression to CRPC-adeno and transdifferentiation to CRPC-NE. One major MiS regulator during that process is the AR-axis, which is re-activated during CRPC-adeno and blocked in CRPC-NE. Molecularly, an increase in MiS dependent splicing promotes changes of transcriptome and proteome. This results in cell cycle activation, increased MAPK signalling and increased DNA repair. U6atac mediated MiS inhibition renders MiS splicing error-prone through increased intron retention and alternative splicing events, which results in cell cycle block and decreased MAPK signalling and DNA repair. MiS inhibition blocks all stages of PCa. Figure created with BioRender.com. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=154 SRC="FIGDIR/small/471104v1_ufig1.gif" ALT="Figure 1"> View larger version (61K): org.highwire.dtl.DTLVardef@1c1c296org.highwire.dtl.DTLVardef@1ce1416org.highwire.dtl.DTLVardef@88d842org.highwire.dtl.DTLVardef@2ddf96_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nucleic Acids Research
1128 papers in training set
Top 1%
10.2%
2
eLife
5422 papers in training set
Top 11%
6.9%
3
Nature Communications
4913 papers in training set
Top 26%
6.9%
4
Cell Reports
1338 papers in training set
Top 6%
6.9%
5
Oncogene
76 papers in training set
Top 0.2%
6.4%
6
iScience
1063 papers in training set
Top 2%
4.9%
7
PLOS Genetics
756 papers in training set
Top 3%
4.9%
8
NAR Cancer
36 papers in training set
Top 0.1%
3.6%
50% of probability mass above
9
Cells
232 papers in training set
Top 0.6%
3.6%
10
Molecular Cancer Research
42 papers in training set
Top 0.1%
3.1%
11
Cancer Research
116 papers in training set
Top 1%
2.1%
12
Nature Genetics
240 papers in training set
Top 4%
1.9%
13
The American Journal of Human Genetics
206 papers in training set
Top 2%
1.7%
14
The EMBO Journal
267 papers in training set
Top 2%
1.7%
15
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.3%
16
Genes & Development
90 papers in training set
Top 0.6%
1.3%
17
Cell Genomics
162 papers in training set
Top 4%
1.3%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 37%
1.2%
19
Genome Medicine
154 papers in training set
Top 6%
1.0%
20
The Prostate
11 papers in training set
Top 0.1%
0.9%
21
EMBO Reports
88 papers in training set
Top 0.4%
0.9%
22
Nucleus
11 papers in training set
Top 0.1%
0.8%
23
Computational and Structural Biotechnology Journal
216 papers in training set
Top 8%
0.8%
24
Molecular Cell
308 papers in training set
Top 9%
0.8%
25
British Journal of Cancer
42 papers in training set
Top 2%
0.8%
26
Life Science Alliance
263 papers in training set
Top 1%
0.8%
27
PLOS Biology
408 papers in training set
Top 21%
0.7%
28
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%
29
EMBO reports
136 papers in training set
Top 7%
0.7%
30
RNA
169 papers in training set
Top 0.5%
0.7%